psammomatous melanotic schwannoma complex

psammomatous melanotic schwannoma complex Post-operative Stereotactic Radiosurgery of Malignant

Name: psammomatous melanotic schwannoma complex Post-operative Stereotactic Radiosurgery of Malignant
Brand: lagence-mr.com
SKU: 35971626254
Price: 23.35 USD
Availability: InStock
Rating: 4.6111 (29 reviews)

Post operative Stereotactic Radiosurgery of Malignant Melanotic Schwannoma Cureus Extramedullary malignant melanotic schwannoma of the spine: Case report and an up to date systematic review of the literature ScienceDirect Melanotic Schwannomas Are Rarely Seen Pigmented Tumors with Unpredictable Prognosis and Challenging Diagnosis PMC Intracranial Melanotic Schwannomas: Rare and Distinctive Tumors to Know Due to their Risk of Recurrence and Metastases Journal of the Belgian Society of Radiology Carney Complex: a familial lentiginosis predisposing to a variety of tumors PMC

SKU: 35971626254 · From lagence-mr.com

4.6

USD23.35 USD68.35

Pay in 4 interest-free payments of $5.84 Learn more

Shipping Estimate
USA

USA

CAN

Ships within 48 hours · Estimated delivery Sep 17 - Sep 22

Description

Science 275 , 11321136 (1997)

Peng JH, Peng HLP

doi: 10.1007/s11154-022-09711-2 [DOI] [PubMed] [Google Scholar] 25.Ozojide KOCVUADAAOOOELJG, Aliu V

this enzyme is essential for the regulation of ferroptosis because it decreases glutathione and increases cellular ROS levels ( Prostaglandin-endoperoxide synthase 2 (PTGS2) encodes the enzyme cyclooxygenase 2, which catalyzes lipid oxidation ( Arachidonic acid 12 lipoxygenase (ALOX12) is also closely associated with p53-mediated ferroptosis ( TP53-induced glycolysis and apoptosis regulator (TIGAR) is a target gene of p53 that inhibits cancer and has an antioxidant effect ( p53 can also promote ferroptosis by influencing the function of ferredoxin reductase (FDXR) in iron metabolism ( 2.2 Negative Regulation of Ferroptosis by p53 In addition to its ferroptosis-promoting effects, p53 represses ferroptosis by inducing cyclin-dependent kinase inhibitor (CDKN1A, encoding p21), Parkinson disease 2 (PARK2) and iPLA2, or by inhibiting dipeptidyl peptidase-4 (DPP4) (Figure 2)